Bulletproofing Pharma Patents


With the high cost of drug development, assurance that a pharma company will be able to market a new drug free of generic competition for a long enough period of time to make the initial investment worthwhile is of great importance. Fish Principals Janis Fraser and Christine Goddard recently offered advice to help pharma companies work towards this assurance, giving their six tips for bulletproofing pharma patents in an article they authored for the Life Sciences IP Review newsletter. Get their tips in the full article here.